We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.
- Authors
Vear, Susan I.; Ayers, Gregory D.; Driest, Sara L.; Sidonio, Robert F.; Stein, Charles Michael; Ho, Richard H.
- Abstract
The influence of genetic variation on warfarin dose requirement is limited for paediatric patients. We performed a retrospective, cross-sectional study to examine the effect of variant CYP2C9 and VKORC1 genotypes on warfarin dose in 100 children. Those with VKORC1 genotype AA required 48% of the dose of homozygous wild-type ( GG, P < 0·0001). Patients with any variant CYP2C9 allele required 71% of the dose for wild-type ( P = 0·001). The effect of variant VKORC1 alleles tended to vary with age, suggesting developmental ontogeny may influence warfarin sensitivity. Age, CYP2C9 genotype, VKORC1 genotype and age: VKORC1 interaction accounted for 53% of warfarin dose variability.
- Subjects
DRUG therapy; WARFARIN; PEDIATRICS; HUMAN genetic variation; PHARMACOGENOMICS; ONTOGENY; DEVELOPMENTAL biology; PATIENTS
- Publication
British Journal of Haematology, 2014, Vol 165, Issue 6, p832
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.12817